AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04065269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: ATR inhibitor
Study NCT04065269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PARP inhibitor
Study NCT04065269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PD-L1 immunotherapy
Study NCT01849263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT01849263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03534804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is administered at 40 mg oral daily
Study NCT03534804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.
Study NCT02581085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol (TCT)
Description: TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.
Study NCT02581085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control study capsule that includes no study product (Vitamin E - Tocotrienol)
Study NCT03659188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cortico-alveolar perforations
Description: Mechanical drills will be used on a handpiece
Study NCT03659188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Corticotomy
Description: Piezo-surgery will be employed following flaps' elevation.
Study NCT02569385 — intervention group
Intervention type: OTHER
Intervention: Spontaneous breathing trial
Study NCT02078206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive stimulation
Study NCT01400308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin + Chlorhexidin
Description: Treatment after protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)
Study NCT01400308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prontoderm MRSA Kit
Description: Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.~Prontoderm® is a Class III medical device
Study NCT02658526 — intervention group
Intervention type: BEHAVIORAL
Intervention: anesthesia - surgery
Study NCT00681460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human recombined insulin
Description: multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
Study NCT00681460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
Study NCT06502912 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02440451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback using BCI
Description: This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.
Study NCT01543932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
Study NCT01543932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
Study NCT01543932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
Study NCT00658684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: 4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
Study NCT01468467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Oral Liquid
Study NCT00636311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide, Gemcitabine, Vinorelbine
Description: Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
Study NCT00636311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib + IGEV
Description: Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
Study NCT03786523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
Study NCT03786523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Energy Restriction
Description: Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on feeding time.
Study NCT01210261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compumedics Somnilink SPAP - Auto-titrating CPAP
Description: Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carryover effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment.
Study NCT01210261 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resmed Autoset S8 - Auto-titrating CPAP
Description: Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carry-over effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment.
Study NCT00632437 — intervention group
Intervention type: PROCEDURE
Intervention: Speckle-Contrast Imaging
Description: Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
Study NCT02580643 — intervention group
Intervention type: BIOLOGICAL
Intervention: APS
Description: intra-articular injection
Study NCT00294515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: 900 mg orally daily for up to 100 days
Study NCT00294515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: 900 mg orally daily for up to 200 days
Study NCT00324675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: 4 mg tablets, bid, 12 months
Study NCT00324675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets per day
Study NCT03553680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-Focused CBT
Description: 10 CBT Sessions to improve emotional regulation and emotional intelligence.
Study NCT00836420 — intervention group
Intervention type: PROCEDURE
Intervention: no intervention
Description: the value of the clinical use of microdialysis monitoring of the brain
Study NCT00802698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal electric stimulation
Description: central artery occlusion
Study NCT00802698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal stimulation
Description: new waveform
Study NCT00802698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcorneal electric stimulation
Description: Novel waveform central artery occlusion
Study NCT00729079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPP
Description: 1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use
Study NCT01941719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced foot care education
Description: In addition to the standard foot care education, personalized, computer-animated plantar pressure maps in both barefoot and in-shoe conditions were demonstrated once at baseline visit. The demonstration includes diabetic foot education on the topic of diabetic neuropathy and how barefoot walking can lead to skin breakdown and ulcer formation, which can lead to infection and eventual amputation. The education also highlights the high plantar pressures experienced by individuals while barefoot versus in-shoe and how proper footwear is necessary in conjunction with other standard self-foot care measures to prevent injury and complications.
Study NCT01941719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Foot Care Education
Description: At baseline, a trained staff individually reviewed and dispensed the following brochures: Prevent diabetes problems: Keep your diabetes under control (NIH Publication No. 07-4349) and Prevent diabetes problems: Keep your feet and skin healthy (NIH Publication No. 07-4282) along with a 1-page summary of each brochure. Also, a 1-page supplementary diabetic shoe wear educational material was reviewed and dispensed. Keep your diabetes under control stresses sugar, blood pressure, and medication control, and nutrition and physical activity, and checking feet daily for cuts, blisters, sores, swelling, redness, or sore toenails. Keep your skin and feet healthy emphasizes the importance of checking feet daily, highlighting diabetic foot complications that can arise from neuropathy, poor circulation and dry skin, and the importance of supportive, protective, and accommodative shoewear and annual foot exams.
Study NCT03614637 — intervention group
Intervention type: OTHER
Intervention: Cannabis use abstinence for 11 weeks
Description: Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.
Study NCT04001231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Once-Weekly Suspension
Description: A single dose will be administered as 2.0-mg dose of exenatide onceweekly suspension via subcutaneous (SC) injection followed by blood samples be drawn for up to 168 hours after the first dose on Day 1 to assess single-dose PK for exenatide once-weekly suspension. Subsequently Patients will receive the second dose of the investigational product (IP) at Visit 6 (Day 8). Thereafter, patients will receive weekly (±1 day) doses of IP up to Visit 18 (Week 14).
Study NCT00638781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmoteplase
Description: Desmoteplase 62.5 µg/kg BW
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Study NCT02486718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Study NCT03736863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib+ SHR-1210（Camrelizumab）
Description: Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab）200 mg，Intravenous injection，q2W
Study NCT03736863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib+ SHR-1316（Adebrelimab）
Description: Apatinib 250mg, q.d.po+SHR-1316（Adebrelimab） 1200 mg，Intravenous injection，q2W
Study NCT03736863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316（Adebrelimab）+SHR-A2009
Description: SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W,
Study NCT03280719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone Radiotherapy
Description: Prone positioning for regional nodal irradiation using the crawl breast couch.
Study NCT03280719 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Acceleration
Description: Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost
Study NCT03280719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supine Radiotherapy
Description: Supine positioning for regional nodal irradiation using breastboard.
Study NCT03280719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supine Radiotherapy
Description: Supine positioning for regional nodal irradiation using breastboard.
Study NCT03280719 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
Study NCT00638781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmoteplase
Description: Desmoteplase 90 µg/kg BW
Study NCT00638781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmoteplase
Description: Desmoteplase 125 µg/kg BW
Study NCT00638781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04161625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital exercise program with support
Description: The Safe Step application includes an instruction movie on how to create and progress an individual exercise program. The exercises, presented in video format, are organized into 10 groups with a main focus on balance (3 groups), lower-limb strength (4 groups), and gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~Participants use the app to plan their exercises, set reminders, register their exercise, and view statistics. A virtual physiotherapist delivers motivational messages and feed-back. At the end of each month the participants receive an email asking them to report any falls during the past month in a short digital survey. These messages also contains a new video with general falls prevention information.~Technical support will be provided weekly at senior meeting sites. Try-out group exercises (step 1-3) will be provided by a local wellness association (Friskis\&Svettis)
Study NCT01240226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose
Study NCT03280719 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionation
Description: Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
Study NCT04191538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conditioning electrical stimulation
Description: Percutaneously, a small needle will be placed alongside the median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
Study NCT04191538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative electrical stimulation
Description: Immediately following carpal tunnel release, needles for electrical stimulation will be placed alongside the visualized median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
Study NCT04191538 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No electrical stimulation
Description: Patients will receive sham stimulation (needles placed, no current delivered) pre- and post-operatively; however, no current will ever be delivered to the nerve. This is the control cohort.
Study NCT04531085 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Operative treatment
Description: Surgery
Study NCT04531085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment
Description: Surgery
Study NCT04531085 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Long arm cast
Description: cast immobilization
Study NCT04531085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long arm cast
Description: cast immobilization
Study NCT01838395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: IV (intravenous administration)
Study NCT01838395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: SC (subcutaneous injection)
Study NCT01240226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Oral repeating dose
Study NCT01412697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake in rural youth
Description: A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
Study NCT05070923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthyLifetime
Description: HL augments existing case management services by focusing on building the participant's personal capacity for independence in self - care skills, health behavior change, and health decision making. The HL program coordinates and interfaces with the enrollee's primary medical provider, case managers, and caregivers as necessary
Study NCT04077073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReIn-Hand
Description: ReIn-Hand assists the hand opening
Study NCT04077073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReIn-Hand
Description: ReIn-Hand assists the hand opening
Study NCT04077073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot
Description: Robot supports the shoulder load
Study NCT02167490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: sentinel node biopsy
Description: Sentinel node biopsy policy